{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-006396","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.870476+00:00","generated_at":"2026-06-01T23:35:03.267364+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Dermata Therapeutics Q1 2024 net loss $3.1M; cash runway into Q3 2024","bullets":["Cash and equivalents $4.7M as of March 31, 2024, down from $7.4M at Dec 31, 2023.","Net loss of $3.1M for Q1 2024; R&D expenses rose to $1.6M on STAR-1 trial costs.","STAR-1 Phase 3 acne trial enrollment on track for completion by end of 2024; topline data expected Q1 2025.","Partnership discussions ongoing for DMT410 topical botulinum toxin; Japanese patent issued for hyperhidrosis.","Company expects current cash to fund operations only into Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-006396","json":"https://secwatch.observer/filing/0001654954-24-006396.json","markdown":"https://secwatch.observer/filing/0001654954-24-006396.md","text":"https://secwatch.observer/filing/0001654954-24-006396.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424006396/0001654954-24-006396-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424006396/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:35:03.267364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"df0c1747845382b3c3714c5b414fc74e6fd09389","claim":"Dermata Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $3.1 million of net loss.","evidence_excerpt":"The decrease in cash and cash equivalents resulted from $3.1 million of net loss for the quarter ended March 31, 2024, and $0.2 million of decreased accrued liabilities, offset by $0.6 million in stock-based compensation expense.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424006396/0001654954-24-006396-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$3.1 million of net loss"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}